Explore

Trendline Trendline
Axsome Therapeutics Reports Strong Financial Growth and New Product Launches in Q2 2026

Axsome Therapeutics Reports Strong Financial Growth and New Product Launches in Q2 2026

Axsome Therapeutics Reports Strong Financial Growth and New Product Launches in Q2 2026
Trendline Trendline
Tenax Therapeutics' Heart Failure Drug Fails in Pivotal Phase 3 Study

Tenax Therapeutics' Heart Failure Drug Fails in Pivotal Phase 3 Study

Tenax Therapeutics' Heart Failure Drug Fails in Pivotal Phase 3 Study
Trendline Trendline
Babcock Wilcox Enterprises Reports Significant Revenue Growth in Q2 2026

Babcock Wilcox Enterprises Reports Significant Revenue Growth in Q2 2026

Babcock Wilcox Enterprises Reports Significant Revenue Growth in Q2 2026
Trendline Trendline
Seadrill Reports Strong Second Quarter 2026 Results with Increased Revenue and Contract Backlog

Seadrill Reports Strong Second Quarter 2026 Results with Increased Revenue and Contract Backlog

Seadrill Reports Strong Second Quarter 2026 Results with Increased Revenue and Contract Backlog
Reuters Reuters
Factbox-Global drugmakers invest billions to boost US presence

Factbox-Global drugmakers invest billions to boost US presence

Aug 10 (Reuters) - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country.
Trendline Trendline
SION Stock Plummets 90% After Cystic Fibrosis Drug Trial Failure

SION Stock Plummets 90% After Cystic Fibrosis Drug Trial Failure

SION Stock Plummets 90% After Cystic Fibrosis Drug Trial Failure
Trendline Trendline
Omeros Corporation to Release Q2 Financial Results Amid Strategic Developments

Omeros Corporation to Release Q2 Financial Results Amid Strategic Developments

Omeros Corporation to Release Q2 Financial Results Amid Strategic Developments
Trendline Trendline
Spyre Therapeutics Launches SPY772 Program and Initiates Phase 2 Trial for Hidradenitis Suppurativa

Spyre Therapeutics Launches SPY772 Program and Initiates Phase 2 Trial for Hidradenitis Suppurativa

Spyre Therapeutics Launches SPY772 Program and Initiates Phase 2 Trial for Hidradenitis Suppurativa
Trendline Trendline
Portnoy Law Firm Initiates Class Action for iTonic Holdings Investors Over Alleged Fraud

Portnoy Law Firm Initiates Class Action for iTonic Holdings Investors Over Alleged Fraud

Portnoy Law Firm Initiates Class Action for iTonic Holdings Investors Over Alleged Fraud
Trendline Trendline
Veru Inc. Advances Obesity Treatment with Novo Nordisk Partnership and Reports Q3 2026 Financials

Veru Inc. Advances Obesity Treatment with Novo Nordisk Partnership and Reports Q3 2026 Financials

Veru Inc. Advances Obesity Treatment with Novo Nordisk Partnership and Reports Q3 2026 Financials
Trendline Trendline
OmniAb Reports Strong Quarterly Performance Driven by Partner Milestones

OmniAb Reports Strong Quarterly Performance Driven by Partner Milestones

OmniAb Reports Strong Quarterly Performance Driven by Partner Milestones
Trendline Trendline
International Flavors Fragrances Reports Strong Q2 Earnings, Plans Strategic Divestitures

International Flavors Fragrances Reports Strong Q2 Earnings, Plans Strategic Divestitures

International Flavors Fragrances Reports Strong Q2 Earnings, Plans Strategic Divestitures